Amneal Pharmaceuticals, Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-93.2% vs price
Base Case (Median)
-71.2% vs price
Bull Case (75th pct.)
-40.8% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-113.06 | -713.8% | High (40%) |
| PE Comparable | $10.90 | -40.8% | Medium (25%) |
| EV/EBITDA | $19.27 | 4.6% | Medium (20%) |
| EV/FCF | $5.30 | -71.2% | Medium (20%) |
| Earnings Power Value | $1.25 | -93.2% | Medium (50%) |
Based on 5 out of 8 methods, AMRX appears overvalued at the current price of $18.42. The base case fair value of $5.30 implies 71.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.